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Myostatin (MSTN) is a negative regulator of muscle growth that is increased following cardiomyocyte stress and has been proposed to play a role in 
cardiac remodeling. We hypothesized that inhibition of MSTN would improve cardiac function and reduce skeletal muscle wasting in experimental 
heart failure (HF). C57BL/6J mice (n=40) were subjected to left anterior descending coronary artery ligation (HF) or no ligation (SHAM). Three 
weeks after surgery, HF was confirmed by echocardiography (echo). HF and SHAM animals were randomly divided into two groups receiving either 
drug (weekly intraperitoneal 12µg/kg dose Myo-Fc)) or vehicle, for 8 weeks. After treatment, echo was repeated, endurance running test (ERT) was 
performed, and mice were sacrificed. MSTN, IGF-1, Akt, P-Akt, p38, P-p38, SMAP2/3 and P-SMAD2/3 levels in heart were measured by western blot.
Myo-Fc treated HF mice displayed an improvement in cardiac function as seen by echo and ERT (p<0.05). HF mice had significantly heavier hearts 
and decreased skeletal muscle mass, which was reversed by MSTN inhibition. MSTN inhibition decreased IGF-1 in HF mice, and prevented HF-
induced upregulation of cardiac MSTN, SMAD 2/3 and P-p38, as well as P-Akt downregulation.
MSTN inhibition improves heart function and reduces HF-induced muscle wasting. Improved cardiac function is by MSTN inhibition is accompanied 
by normalization of cardiac Akt/p38 signaling. MSTN inhibition has important implications for HF therapy targeting cardiac remodeling and cachexia.
Table 1. Cardiac and Skeletal Muscle changes in HF Mice. (*p<0.05 vs. SHAM, #p<0.05 vs. HF) 
SHAM (n=9) SHAM+ Myo-Fc (n=6) HF (n=10) HF+ Myo-FC (n=9)
Fractional Shortening (% change after treatment) - - -13.1 ± 4.9 41.8± 14.2#
Heart (mg/g bw) 43 ± 1 57 ± 3* 90 ± 5* 58 ± 2 #
Gastrocnemius (mg/g bw) 110 ± 3 129 ± 4* 103 ± 1* 125 ± 1*#
Heart MSTN 100 ± 2 104 ± 1 157 ± 2* 139 ± 5*#
Heart P-SMAD2/3 /SMAD 2/3 100 ± 3 79 ± 3* 155 ± 18* 62 ± 14*#
Heart IGF-1 100 ± 3 78 ± 11 112 ± 2 96 ±12#
Heart P-Akt/Akt 100 ± 8 91 ± 10 41 ± 5* 79 ± 9#
Heart P-p38/p38 100 ± 9 78 ± 4* 147± 8* 75 ± 13*#
